Reading the tape
NASDAQ: STAA
STAAR Surgical Company
Healthcare · Medical - Instruments & Supplies
Market Cap
$1.35B
52w High
$30.81
52w Low
$15.59
P/E
-16.84
Volume
116.16K
Outstanding Shares
49.51M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 44.84%Revenue (TTM): -23.72%FCF (TTM): -500.5%P/E: 0th pct
What changed
The stock rose 44.84% over the last year. Revenue declined 23.72% over the trailing twelve months. Operating margin moved from -4.02% to -33.31%. Free cash flow declined 500.5% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -33.31%. A decisive move in revenue — currently down 23.72% — would be the clearest signal to resolve the ambiguity.
Company profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
CEOWarren Foust
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees1,157
IPO dateFeb 24, 1992
Valuation
Forward P/E—
EV/EBITDA-28.37
Enterprise value$1.06B
Stock splits
May 18, 1992↓ Reverse
Every 2 shares became 1
Nov 1, 1990↓ Reverse
Every 2 shares became 1
Nov 9, 1984↑ Forward
Every 1 shares became 2
Jul 3, 1984↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth18.08%
Gross margin75.63%▼3.20%vs FY2024
Operating margin-33.31%▼376.86%vs FY2024
ROE-23.37%▼359.58%vs FY2024
Analyst consensus
RatingHold
Target price$22.95▼16.04%
3
Buy
11
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.13 · Revenue est $78.72M
View